How Bacterial Pathogens Eat Host Lipids: Implications for the Development of Fatty Acid Synthesis Therapeutics

Bacterial type II fatty acid synthesis (FASII) is a target for the development of novel therapeutics. Bacteria incorporate extracellular fatty acids into membrane lipids, raising the question of whether pathogens use host fatty acids to bypass FASII and defeat FASII therapeutics. Some pathogens supp...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of biological chemistry 2015-03, Vol.290 (10), p.5940-5946
Main Authors: Yao, Jiangwei, Rock, Charles O.
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - therapeutic use
Antibiotics
Bacteria
Bacteria - pathogenicity
FASII
Fatty Acid
Fatty Acid Synthase (FAS)
Fatty Acid Synthase, Type II - antagonists & inhibitors
Fatty Acid Synthase, Type II - genetics
Fatty Acid Synthase, Type II - metabolism
Fatty Acid Transport
Fatty Acids - biosynthesis
Fatty Acids - metabolism
Host-Pathogen Interactions - genetics
Humans
Lipogenesis - genetics
Membrane Lipids - genetics
Membrane Lipids - metabolism
Minireviews
Phospholipid
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bacterial type II fatty acid synthesis (FASII) is a target for the development of novel therapeutics. Bacteria incorporate extracellular fatty acids into membrane lipids, raising the question of whether pathogens use host fatty acids to bypass FASII and defeat FASII therapeutics. Some pathogens suppress FASII when exogenous fatty acids are present to bypass FASII therapeutics. FASII inhibition cannot be bypassed in many bacteria because essential fatty acids cannot be obtained from the host. FASII antibiotics may not be effective against all bacteria, but a broad spectrum of Gram-negative and -positive pathogens can be effectively treated with FASII inhibitors.
ISSN:0021-9258
1083-351X
DOI:10.1074/jbc.R114.636241